[Adverse effects of thromboxane receptor antagonists and synthase inhibitors].
Obayashi
Oji
O
Department of Internal Medicine, Teikyo University School of Medicine.
Ohta
Ken
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018926:Anti-Allergic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy; D016227:Benzoquinones / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006538:Heptanoic Acids / Q000009:adverse effects*; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008297:Male; D008689:Methacrylates / Q000009:adverse effects*; D008875:Middle Aged; D044244:Receptors, Thromboxane A2, Prostaglandin H2 / Q000037:antagonists & inhibitors*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D018926:Anti-Allergic Agents; D016227:Benzoquinones; D004791:Enzyme Inhibitors; D006538:Heptanoic Acids; D008689:Methacrylates; D044244:Receptors, Thromboxane A2, Prostaglandin H2; C060230:seratrodast; D013930:Thromboxane-A Synthase; C034364:ozagrel